Candriam S.C.A. Zai Lab LTD Transaction History

Candriam S.C.A.

$16.9 Billion
Q4 2024

A detailed history of Candriam S.C.A. transactions in Zai Lab LTD stock. As of the latest transaction made, Candriam S.C.A. holds 375,479 shares of ZLAB stock, worth $13.5 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

375,479

Previous 390,023 3.73%

Holding current value

$13.5 Million

Previous $9.42 Million 4.44%

% of portfolio

0.06%

Previous 0.06%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 06, 2025	SELL	$24.61 - $33.18 $357,927 - $482,569	-14,544 Reduced 3.73%	375,479 $9.83 Million
Q3 2024 Nov 13, 2024	BUY	$16.25 - $24.14 $406,412 - $603,741	25,010 Added 6.85%	390,023 $9.42 Million
Q2 2024 Aug 05, 2024	SELL	$13.72 - $21.55 $2.33 Million - $3.66 Million	-170,000 Reduced 31.77%	365,013 $6.33 Million
Q1 2024 May 03, 2024	BUY	$15.95 - $26.8 $3.35 Million - $5.63 Million	210,000 Added 64.61%	535,013 $8.57 Million
Q4 2023 Feb 14, 2024	BUY	$22.97 - $30.58 $7.47 Million - $9.94 Million	325,013 New	325,013 $8.88 Million
Q1 2022 May 13, 2022	SELL	$27.77 - $64.4 $2.99 Million - $6.93 Million	-107,546 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$54.9 - $105.21 $177,381 - $339,933	3,231 Added 3.1%	107,546 $6.76 Million
Q3 2021 Nov 09, 2021	BUY	$105.0 - $178.37 $3.9 Million - $6.63 Million	37,167 Added 55.35%	104,315 $11 Million
Q2 2021 Jul 20, 2021	BUY	$125.11 - $180.0 $8.4 Million - $12.1 Million	67,143 Added 1342860.0%	67,148 $13.2 Million
Q1 2021 Apr 29, 2021	BUY	$126.27 - $191.71 $631 - $958	5 New	5 $1,000

Others Institutions Holding ZLAB

# of Institutions

146

Shares Held

53M

Call Options Held

103K

Put Options Held

439K

View Full List

About Zai Lab Ltd

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $3.52B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

More about ZLAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account